Â鶹ŮÓÅ

Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • Â鶹ŮÓÅ Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Emergency Room Boarding
  • Device Coverage by Medicare
  • Planned Parenthood Funding
  • Covid/Flu Combo Shot
  • RFK Jr. vs. Congress

TRENDING TOPICS:

  • Emergency Room Boarding
  • Device Coverage by Medicare
  • Planned Parenthood Funding
  • Covid/Flu Combo Shot
  • RFK Jr. vs. Congress

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Friday, Jan 24 2025

Full Issue

Sacklers Increase Purdue Settlement Offer, With An Added Condition

The New York Times reports that the tentative $7.4 billion agreement with 15 states would also require those states to set aside as much as $800 million in what amounts to a legal defense fund for the Sackler family. Other pharmaceutical news is on Prime Therapeutics, a potential norovirus vaccine, vaccine hesitancy, and more.

Seven months after the Supreme Court struck down a deal that would have resolved thousands of opioid cases against Purdue Pharma, the company’s owners, members of the Sackler family, have increased their cash offer to settle the litigation — but with a novel catch. Under the framework for a new deal, the Sacklers would not receive immunity from future opioid lawsuits, a condition that they had long insisted upon but that the court ruled was impermissible. (Hoffman, 1/23)

In other pharmaceutical news —

An arbitrator has determined Prime Therapeutics violated federal and state antitrust laws against the AIDS Healthcare Foundation (AHF) and independent pharmacies. In a ruling (PDF) handed down Jan. 17, the AHF was awarded more than $10 million and injunctive relief after Prime Therapeutics was found to engage in horizontal price-fixing with Cigna’s pharmacy benefit manager (PBM), Express Scripts. (Tong, 1/23)

More thyroid cancers were detected soon after starting a GLP-1 receptor agonist than other diabetes drugs, a secondary analysis of a target trial emulation of a comparative effectiveness study found. ... But when the analysis was broadened beyond year one -- now looking at any length of time since treatment initiation -- GLP-1 agonist use wasn't significantly tied with thyroid cancer compared with the three other diabetes drug classes (HR 1.24, 95% CI 0.88-1.76), they wrote in JAMA Otolaryngology-Head & Neck Surgery. (Monaco, 1/23)

On vaccines and vaccine hesitancy —

Norovirus is raging across the U.S. this winter. Moderna might soon have a vaccine for it. A large phase three trial of the shot is underway, with results expected as soon as later this year or 2026. Moderna needs to see a certain number of cases before it can analyze the data and determine how well its vaccine works, putting the timeline in flux. The 25,000-person study is enrolling ahead of schedule, said Doran Fink, Moderna’s clinical therapeutic area head for gastrointestinal and bacterial pathogens. (Peebles, 1/23)

R.F.K. Jr. and others have blamed the ingredient for allergies and other illnesses. Scientists say it actually bolsters the immune response. (Rosenbluth, 1/24)

In pediatricians’ offices across the country, doctors are increasingly confronting concerns from parents about vaccines that for decades have protected children from serious and sometimes deadly diseases. Vaccine hesitancy is nothing new. But physicians say this skepticism has gained new momentum in recent years as vaccine misinformation has become widespread on social media, and as more Americans have become distrustful of the medical establishment. (Moyer, 1/24)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Monday, April 27
  • Friday, April 24
  • Thursday, April 23
  • Wednesday, April 22
  • Tuesday, April 21
  • Monday, April 20
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Republish Our Content
  • Contact Us

Follow Us

  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 Â鶹ŮÓÅ